Losartan Potassium
Product Images NDC 68071-2786

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 68071-2786). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2786 1)

Label for Losartan Potassium 100 mg tablets by NuCare Pharmaceuticals, Inc. The bottle contains 120 round, white to off-white tablets engraved with "S" on one side and "113" on the reverse. The label includes NDC 68071-2786, directions to take as prescribed, storage instructions at 68-77°F, and warnings to keep out of reach of children.*

FDA Label Image

Chemical Structure (Spl Image1 Structure1)

Chemical structure diagram of losartan potassium, showing its atomic arrangement including chlorine, hydroxyl, and potassium ion components.*

FDA Label Image

Figure 1 (Spl Image2 Figure1)

A line graph comparing the percentage of patients with the primary endpoint over study months between Atenolol and Losartan Potassium. The x-axis represents the study month (0 to 66), and the y-axis shows the percentage of patients (0 to 16%). Data indicate an adjusted risk reduction of 13% for Losartan Potassium with a p-value of 0.021.*

FDA Label Image

Figure 2 (Spl Image3 Figure2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over study months for Atenolol (dotted line) and Losartan Potassium (solid line). The graph shows adjusted risk reduction of 25% with a p-value of 0.001, indicating statistical significance.*

FDA Label Image

Figure 3 (Spl Image4 Figure3)

A forest plot chart showing primary endpoint events within demographic subgroups comparing Losartan Potassium and Atenolol. The chart presents hazard ratios with 95% confidence intervals for primary composite and stroke (fatal/non-fatal) outcomes, broken down by age, gender, race, ISH, diabetes, and history of cardiovascular disease. Symbol sizes indicate sample size.*

FDA Label Image

Figure 4 (Spl Image5 Figure4)

A line graph comparing the percentage of patients with events over 48 months for Losartan Potassium versus placebo. The graph includes a risk reduction value of 16.1% and a p-value of 0.022, illustrating a difference between the two groups over time.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.